CPL304110 is currently under clinical investigation (Phase I: NCT4149691, 01FGFR2018); after completing the part without molecular selection of patients, the following part will include the selection of patients with chosen aberrations in FGFR1, 2, and 3 genes in lung, stomach, and bladder cancers, respectively. Here, FGFR1 is linked to urinary bladder carcinoma.